Short-course radiation with immunotherapy and chemo for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have rectal adenocarcinoma that has not spread to other organs (stage I, II, or III).
- The tumor is within 5 cm of your anus and is the MSS/pMMR type.
- You have not had any prior treatment for rectal cancer, like chemotherapy, radiation, or immunotherapy.
- You are in good general health, with adequate blood counts and organ function, and no active autoimmune disease or other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a new combination of short-course radiation, an immunotherapy drug called ivonescimab, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a shorter course of radiation given with chemotherapy and immunotherapy before surgery for rectal cancer that has high-risk features. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.